Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-19T13:27:08.498Z Has data issue: false hasContentIssue false
  • English
  • Français

Establishing cost-effectiveness of antipsychotic drugs

Published online by Cambridge University Press:  03 January 2018

Clive E. Adams
Clive E. Adams*
Affiliation:
Summertown Pavilion, Middle Way, Oxford OX2 7LG
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Information
The British Journal of Psychiatry , Volume 171 , Issue 5 , November 1997 , pp. 486
Copyright
Copyright © 1997 The Royal College of Psychiatrists 

References

Adams, C. E., Soares, K. (1997) The Cochrane Collaboration and the process of systematic reviewing. Advances in Psychiatric Treatment, 3, 240–246.Google Scholar
Kennedy, E., Song, F., Hunter, R., et al (1997) Risperidone for schizophrenia. The Cochrane Library (CD-ROM). The Cochrane Collaboration; Issue 3. Oxford: Update Software.Google Scholar
Robert, G. & Kennedy, P. (1997) Establishing cost-effectiveness of atypical neuroleptics. British Journal of Psychiatry, 171, 103–104.Google Scholar
Wahlbeck, K., Cheine, M., Essali, M. A., et al (1997) Clozapine vs ‘typical’ neuroleptic medication for schizophrenia. The Cochrane Library (CD-ROM). The Cochrane Collaboration; Issue 3. Oxford: Update Software.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.